{"title":"Is human oversight to AI systems still possible?","authors":"Andreas Holzinger, Kurt Zatloukal, Heimo Müller","doi":"10.1016/j.nbt.2024.12.003","DOIUrl":null,"url":null,"abstract":"<p><p>The rapid proliferation of artificial intelligence (AI) systems across diverse domains raises critical questions about the feasibility of meaningful human oversight, particularly in high-stakes domains such as new biotechnology. As AI systems grow increasingly complex, opaque, and autonomous, ensuring responsible use becomes a formidable challenge. During our editorial work for the special issue \"Artificial Intelligence for Life Sciences\", we placed increasing emphasis on the topic of \"human oversight\". Consequently, in this editorial we briefly discuss the evolving role of human oversight in AI governance, focusing on the practical, technical, and ethical dimensions of maintaining control. It examines how the complexity of contemporary AI architectures, such as large-scale neural networks and generative AI applications, undermine human understanding and decision-making capabilities. Furthermore, it evaluates emerging approaches-such as explainable AI (XAI), human-in-the-loop systems, and regulatory frameworks-that aim to enable oversight while acknowledging their limitations. Through a comprehensive analysis, the picture emerged while complete oversight may no longer be viable in certain contexts, strategic interventions leveraging human-AI collaboration and trustworthy AI design principles can preserve accountability and safety. The discussion highlights the urgent need for interdisciplinary efforts to rethink oversight mechanisms in an era where AI may outpace human comprehension.</p>","PeriodicalId":19190,"journal":{"name":"New biotechnology","volume":" ","pages":"59-62"},"PeriodicalIF":4.5000,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"New biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1016/j.nbt.2024.12.003","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0
Abstract
The rapid proliferation of artificial intelligence (AI) systems across diverse domains raises critical questions about the feasibility of meaningful human oversight, particularly in high-stakes domains such as new biotechnology. As AI systems grow increasingly complex, opaque, and autonomous, ensuring responsible use becomes a formidable challenge. During our editorial work for the special issue "Artificial Intelligence for Life Sciences", we placed increasing emphasis on the topic of "human oversight". Consequently, in this editorial we briefly discuss the evolving role of human oversight in AI governance, focusing on the practical, technical, and ethical dimensions of maintaining control. It examines how the complexity of contemporary AI architectures, such as large-scale neural networks and generative AI applications, undermine human understanding and decision-making capabilities. Furthermore, it evaluates emerging approaches-such as explainable AI (XAI), human-in-the-loop systems, and regulatory frameworks-that aim to enable oversight while acknowledging their limitations. Through a comprehensive analysis, the picture emerged while complete oversight may no longer be viable in certain contexts, strategic interventions leveraging human-AI collaboration and trustworthy AI design principles can preserve accountability and safety. The discussion highlights the urgent need for interdisciplinary efforts to rethink oversight mechanisms in an era where AI may outpace human comprehension.
期刊介绍:
New Biotechnology is the official journal of the European Federation of Biotechnology (EFB) and is published bimonthly. It covers both the science of biotechnology and its surrounding political, business and financial milieu. The journal publishes peer-reviewed basic research papers, authoritative reviews, feature articles and opinions in all areas of biotechnology. It reflects the full diversity of current biotechnology science, particularly those advances in research and practice that open opportunities for exploitation of knowledge, commercially or otherwise, together with news, discussion and comment on broader issues of general interest and concern. The outlook is fully international.
The scope of the journal includes the research, industrial and commercial aspects of biotechnology, in areas such as: Healthcare and Pharmaceuticals; Food and Agriculture; Biofuels; Genetic Engineering and Molecular Biology; Genomics and Synthetic Biology; Nanotechnology; Environment and Biodiversity; Biocatalysis; Bioremediation; Process engineering.